Aldara gets FDA nod for treatment of sBCC

St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

Related Videos
Related Content

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023

Metal Implants Can Lead to Allergic Contact Dermatitis

March 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Mediterranean Diet May Improve Responses to Immune Checkpoint Blockade for Advanced Melanoma

March 24th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Highlights from AAD 2023

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.